Immune cell boost could keep leukemia at bay after transplant

NCT ID NCT05015426

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether infusing specially grown donor immune cells (gamma delta T-cells) can prevent acute myeloid leukemia from returning in patients who are at high risk of relapse after a stem cell transplant. About 20 adults aged 18–75 will receive a single infusion of these cells. The study aims to find the safest dose and see if it improves leukemia-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor gamma delta T-cells (a type of immune cell)
What this could lead to: If it works, this could offer a new way to prevent leukemia from coming back after a stem cell transplant, without needing long-term drugs.
What could go wrong: This is a very early, small trial (20 people) focused on safety and dosing. The cells may cause graft-versus-host disease or fail to prevent relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.